Arendt & Medernach advises Aztiq in connection with the sale of a majority stake in Aldavo to EQT

Experts involved in the Deal

Arendt advises Aztiq in its definitive agreement with EQT, a leading global investment firm with a strong track record of owning and developing healthcare companies around the world, in connection with the sale of a majority stake in Aldavo, a leading asset-light B2B dossier developer.

As part of the transaction existing shareholders, including Aztiq, the holding company of Adalvo’s current Chairman Róbert Wessman, will reinvest part of their existing holdings and remain minority shareholders.

This strategic move marks a significant milestone in Adalvo’s journey as a rapidly expanding global business-to-business (B2B) pharmaceutical company. Established in 2018, Adalvo has rapidly positioned itself as a key player in the global B2B space, building up a position as a leading dossier developer in the years since its foundation. With a strong focus on international markets and a reputation as a leading dossier development house, the company has built an impressive track record of growth.

The transaction is subject to customary regulatory conditions and approvals. It is expected to close during H2 2025.